Association of adolescent lipoprotein subclass profile with carotid intima-media thickness and comparison to adults: Prospective population-based cohort studies.


Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
01 2022
Historique:
received: 26 04 2021
revised: 09 12 2021
accepted: 10 12 2021
pubmed: 8 1 2022
medline: 2 2 2022
entrez: 7 1 2022
Statut: ppublish

Résumé

Assessment of comprehensive lipoprotein subclass profiles in adolescents and their relation to vascular disease may enhance our understanding of the development of dyslipidemia in early life and inform early vascular prevention. Nuclear magnetic resonance was used to measure lipoprotein profiles, including lipids (cholesterol, free cholesterol, triglycerides, phospholipids) and apolipoproteins (apoB-100, apoA1, apoA2) of 17 lipoprotein subclasses (from least dense to densest: VLDL-1 to -6, IDL, LDL-1 to -6, HDL-1 to -4) in n = 1776 14- to 19-year olds (56.6% female) and n = 3027 25- to 85-year olds (51.5% female), all community-dwelling. Lipoprotein profiles were related to carotid intima-media thickness (cIMT) as ascertained by sonography. Adolescents compared to adults had lower triglycerides, total, LDL, and non-HDL cholesterol, and apoB, and higher HDL cholesterol. They showed 26.6-59.8% lower triglyceride content of all lipoprotein subclasses and 21.9-51.4% lower VLDL lipid content. Concentrations of dense LDL-4 to LDL-6 were 36.7-40.2% lower, with also markedly lower levels of LDL-1 to LDL-3, but 24.2% higher HDL-1 ApoA1. In adolescents, only LDL-3 to LDL-5 subclasses were associated with cIMT (range of differences in cIMT for a 1-SD higher concentration, 4.8-5.9 μm). The same associations emerged in adults, with on average 97 ± 42% (mean ± SD) larger effect sizes, in addition to LDL-1 and LDL-6 (range, 6.9-11.3 μm) and HDL-2 to HDL-4, ApoA1, and ApoA2 (range, -7.0 to -17.7 μm). Adolescents showed a markedly different and more favorable lipoprotein profile compared to adults. Dense LDL subclasses were the only subclasses associated with cIMT in adolescents, implicating them as the potential preferred therapeutic target for primary prevention of cardiovascular disease at this age. In adults, associations with cIMT were approximately twice as large as in adolescents, and HDL-related measures were additionally associated with cIMT.

Sections du résumé

BACKGROUND AND AIMS
Assessment of comprehensive lipoprotein subclass profiles in adolescents and their relation to vascular disease may enhance our understanding of the development of dyslipidemia in early life and inform early vascular prevention.
METHODS
Nuclear magnetic resonance was used to measure lipoprotein profiles, including lipids (cholesterol, free cholesterol, triglycerides, phospholipids) and apolipoproteins (apoB-100, apoA1, apoA2) of 17 lipoprotein subclasses (from least dense to densest: VLDL-1 to -6, IDL, LDL-1 to -6, HDL-1 to -4) in n = 1776 14- to 19-year olds (56.6% female) and n = 3027 25- to 85-year olds (51.5% female), all community-dwelling. Lipoprotein profiles were related to carotid intima-media thickness (cIMT) as ascertained by sonography.
RESULTS
Adolescents compared to adults had lower triglycerides, total, LDL, and non-HDL cholesterol, and apoB, and higher HDL cholesterol. They showed 26.6-59.8% lower triglyceride content of all lipoprotein subclasses and 21.9-51.4% lower VLDL lipid content. Concentrations of dense LDL-4 to LDL-6 were 36.7-40.2% lower, with also markedly lower levels of LDL-1 to LDL-3, but 24.2% higher HDL-1 ApoA1. In adolescents, only LDL-3 to LDL-5 subclasses were associated with cIMT (range of differences in cIMT for a 1-SD higher concentration, 4.8-5.9 μm). The same associations emerged in adults, with on average 97 ± 42% (mean ± SD) larger effect sizes, in addition to LDL-1 and LDL-6 (range, 6.9-11.3 μm) and HDL-2 to HDL-4, ApoA1, and ApoA2 (range, -7.0 to -17.7 μm).
CONCLUSIONS
Adolescents showed a markedly different and more favorable lipoprotein profile compared to adults. Dense LDL subclasses were the only subclasses associated with cIMT in adolescents, implicating them as the potential preferred therapeutic target for primary prevention of cardiovascular disease at this age. In adults, associations with cIMT were approximately twice as large as in adolescents, and HDL-related measures were additionally associated with cIMT.

Identifiants

pubmed: 34995985
pii: S0021-9150(21)01490-8
doi: 10.1016/j.atherosclerosis.2021.12.007
pii:
doi:

Substances chimiques

Cholesterol, HDL 0
Lipoproteins 0
Triglycerides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-42

Subventions

Organisme : British Heart Foundation
ID : CH/16/3/32406
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/16/3/32 406
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/14/32397
Pays : United Kingdom

Investigateurs

Anna Staudt (A)
Benoà T Bernar (BT)
Bernhard Winder (B)
Carmen Reiter (C)
Christina Burger (C)
Christoph Hochmayr (C)
Gregor Brà Ssner (G)
Hermann Stuppner (H)
Julia Klingenschmid (J)
Julia Marxer (J)
Katharina Stock (K)
Mandy Asare (M)
Manuel Mayr (M)
Manuela Bock-Bartl (M)
Martina Kothmayer (M)
Maximilian Bohl (M)
Maximilian Pircher (M)
Michael Knoflach (M)
Nina Gande (N)
Raimund Pechlaner (R)
Ralf Geiger (R)
Sonja Sturm (S)
Sophia J Kiechl (SJ)
Stefan Kiechl (S)
Tatjana Heisinger (T)
Ursula Kiechl-Kohlendorfer (U)

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Raimund Pechlaner (R)

Department of Neurology, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Nele Friedrich (N)

Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; German Centre for Cardiovascular Research, Partner Site Greifswald, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

Anna Staudt (A)

Department of Pediatrics II, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Nina Gande (N)

Department of Pediatrics II, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Benoît Bernar (B)

Department of Pediatrics II, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria; Department of Pediatrics I, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Katharina Stock (K)

Department of Pediatrics II, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria; Department of Pediatrics III, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Sophia J Kiechl (SJ)

Department of Neurology, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria; VASCage, Research Centre for Promoting Vascular Health in the Ageing Community, Innrain 66a, 6020 Innsbruck, Austria.

Christoph Hochmayr (C)

Department of Pediatrics II, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Andrea Griesmacher (A)

Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.

Astrid Petersmann (A)

Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Rahel-Strauss-Straße 10, 26133 Oldenburg, Germany.

Kathrin Budde (K)

Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

Hermann Stuppner (H)

Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Innrain 52, 6020 Innsbruck, Austria.

Sonja Sturm (S)

Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Innrain 52, 6020 Innsbruck, Austria.

Marcus Dörr (M)

German Centre for Cardiovascular Research, Partner Site Greifswald, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; Department of Internal Medicine B, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

Ulf Schminke (U)

Department of Neurology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

Claire Cannet (C)

Bruker BioSpin, Silberstreifen 4, 76287 Rheinstetten, Germany.

Fang Fang (F)

Bruker BioSpin, Silberstreifen 4, 76287 Rheinstetten, Germany.

Hartmut Schäfer (H)

Bruker BioSpin, Silberstreifen 4, 76287 Rheinstetten, Germany.

Manfred Spraul (M)

Bruker BioSpin, Silberstreifen 4, 76287 Rheinstetten, Germany.

Ralf Geiger (R)

Department of Pediatrics III, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Manuel Mayr (M)

King's British Heart Foundation Centre, King's College London, 125 Coldharbour Ln, SE5 9NU London, United Kingdom.

Matthias Nauck (M)

Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; German Centre for Cardiovascular Research, Partner Site Greifswald, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

Stefan Kiechl (S)

Department of Neurology, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria; VASCage, Research Centre for Promoting Vascular Health in the Ageing Community, Innrain 66a, 6020 Innsbruck, Austria. Electronic address: stefan.kiechl@i-med.ac.at.

Ursula Kiechl-Kohlendorfer (U)

Department of Pediatrics II, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Michael Knoflach (M)

Department of Neurology, Medical University of Innsbruck, Christoph-Probst-Platz 1, Innrain 52 A, 6020 Innsbruck, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH